close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atai Beckley N.V - Common Shares (NQ:ATAI)

3.800 +0.140 (+3.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atai Beckley N.V - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
News headline image
Nucor, Waste Management And 3 Stocks To Watch Heading Into Monday ↗
 
Via Benzinga
News headline image
Top movers in Friday's after hours session ↗
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
From atai Life Sciences
Via GlobeNewswire
DOD to Invest $9.8m into Psychedelic Studies Targeting Active-Duty Soldiers
Via Investor Brand Network
News headline image
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
From FN Media Group LLC
Via GlobeNewswire
News headline image
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data ↗
Atai and Beckley report that a single dose of BPL-003 reduced depression symptoms significantly and safely in treatment-resistant patients. 
Via Benzinga
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Get insights into the top gainers and losers of Tuesday's pre-market session. ↗
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
atai Life Sciences Announces $50 Million Private Placement Financing
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 
From atai Life Sciences
Via GlobeNewswire
News headline image
5 Biotech Stocks with Highly Anticipated Pending Results ↗
Via Stocktwits
Topics Intellectual Property
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
News headline image
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Atai Life Sciences Stock Rockets On Merger Plans With Beckley Psytech; Retail Traders Eye Every Dip ↗
The merger focuses on creating a combined company focused on psychedelic mental health therapies. 
Via Stocktwits
News headline image
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences to Participate in Upcoming Investor Conferences
From atai Life Sciences
Via GlobeNewswire
News headline image
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
News headline image
Atai Life Sciences Stock Soars To 3-Month High As Depression Study Yields Promising Results: Retail Bulls Cheer ↗
Atai Life Sciences shares surged 11.4% after Beckley Psytech reported encouraging Phase 2a results of its depression treatment 
Via Stocktwits
News headline image
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From atai Life Sciences
Via GlobeNewswire
News headline image
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Study Finds That Bad Psychedelic Trips Double Some Individuals’ Fatality Risk
Via Investor Brand Network
News headline image
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today